Work

P3.04-012 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC

Year: 2017

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2017.09.1670

Authors: P. Jänne, H. Yu, M. Vigliotti, N. Shipitofsky, J. Li, J. Mcgill, C. Yu

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2767651377

FWCI:

Cites:

Cited by: 1

Related to: 10